Constipation on a semaglutide tablet: where the symptom ends and the warning starts

Before you read. This page explains what the FDA label says. It is educational, it cannot assess your symptoms, and it is not a treatment plan. Some of what follows is not a wait-and-see situation. If you have not passed stool or gas, or you have persistent vomiting, a swollen or hard abdomen, or severe abdominal pain, contact your care team or emergency services now rather than reading further — those are the features of a bowel obstruction, which the label lists among the reactions reported after approval. For anything short of that, a pharmacist is the right first call before starting any laxative, because what is suitable depends on your other medicines and conditions.

Quick answer

Constipation is in the label's adverse reactions table, and the number is unremarkable: more common on the drug than on placebo, and it does not climb with dose the way nausea does. The frequency table, symptom by symptom has that row in full.

The part worth knowing is elsewhere. The postmarketing section — reactions reported after approval rather than counted in trials — names four things in one line: ileus, intestinal obstruction, severe constipation including fecal impaction.

That is a spectrum, not a synonym list. Most constipation on this drug is ordinary constipation. What the label is flagging is that the tail exists, and the features that mark the tail are specific enough to check against.

Two practical points follow. The mechanism is the drug working, not the drug malfunctioning — slowed gastric emptying is part of how it lowers post-meal glucose. And the obvious remedy has a trap in it: adding fibre without adding fluid tends to make things worse, and the label carries a separate warning about kidney injury from volume depletion.

Log the symptom against the dose change →

The number, and where the fuller version lives

Briefly, because it is covered properly elsewhere and repeating it here would help nobody.

Constipation appears in the table of adverse reactions reported in 5% or more of patients on semaglutide tablets, alongside nausea, abdominal pain, diarrhoea, decreased appetite and vomiting. Unlike nausea, it does not increase across the dose steps — the 7 mg figure is slightly higher than the 14 mg one.

For the whole table read in order, with the placebo column beside it, the full side-effect picture, dose by dose is the page for it.

One number from a different part of the label is more useful here than the frequency: severe gastrointestinal adverse reactions were reported in 0.6% of patients on 7 mg and 2% on 14 mg, against 0.3% on placebo. Severe is the label's own category, and it is where this page is aimed.

Why a drug that slows the stomach slows more than the stomach

The label's pharmacodynamics section describes a delay in gastric emptying in the early postprandial phase as one of the mechanisms by which semaglutide lowers blood glucose. Food leaves the stomach more slowly, glucose arrives more slowly, and the post-meal peak is lower.

That slowing is the point — and it is also, in a proportion of people, felt further down.

Two ordinary consequences compound it, and neither is a side effect in itself. Eating less means less bulk moving through. And a suppressed appetite usually means less drinking, because a good deal of daily fluid arrives with meals rather than from a glass. Slower transit, less bulk, less fluid — a combination that produces constipation without anything going wrong.

The same delayed emptying is what matters before a procedure requiring anaesthesia, for a different reason and with different consequences. It is the single most far-reaching property of this class of drug.

The postmarketing line, read carefully

Here is the entry in full, from the gastrointestinal bullet of the postmarketing experience section:

acute pancreatitis and necrotizing pancreatitis, sometimes resulting in death; ileus, intestinal obstruction, severe constipation including fecal impaction

Three things about how to read that.

Postmarketing means reported, not measured. The label says so directly: these reactions are reported voluntarily from a population of uncertain size, so it is not always possible to reliably estimate their frequency or establish a causal relationship. No percentage exists for any of them and none can be inferred.

The list is ordered by severity, and it is a continuum. Severe constipation and faecal impaction sit at one end. Ileus — the gut stopping its propulsive movement — and intestinal obstruction sit at the other, and both are medical emergencies rather than worse versions of a nuisance.

It is listed because it was reported, which is the reason to know the features rather than the reason to expect it. The overwhelmingly likely version of constipation on this drug is the ordinary one.

The features that separate the two. Ordinary constipation is infrequent, hard or difficult stools, usually with gas still passing. The pattern that needs urgent assessment is no stool and no gas, particularly with vomiting, a distended or hard abdomen, or severe cramping pain. That combination is how a bowel obstruction presents, and it does not respond to waiting or to a laxative.

The dehydration trap

This is where the two warnings in the label meet, and it is the most useful thing on this page.

Section 5.5 warns about acute kidney injury due to volume depletion, with postmarketing reports of acute kidney injury in some cases requiring haemodialysis. The label's own framing of the mechanism is specific: the majority of the reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration.

Constipation is not usually thought of as a dehydrating condition, and that is exactly the problem. Someone with a suppressed appetite drinking less than usual, adding fibre supplements to a low fluid intake, and perhaps taking an osmotic laxative that draws water into the bowel, can end up more volume-depleted than anyone in that sequence intended.

The label's instruction is to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during dosage initiation and escalation. The kidney warning and what triggers it covers that section in full.

The practical version: fluid is not optional alongside any of the usual constipation measures, and it is the thing most likely to be quietly short.

Constipation is a pattern question, and patterns need dates. Takely puts your dose changes and a one-line note on each day on the same private timeline, so "since the increase" is something you can show rather than estimate. Open Takely in your browser →

Fibre, fluid, and the trap in the obvious answer

The advice that circulates is adequate fibre and generous water, and it comes from expert consensus rather than from the label — the label restricts what happens in the 30 minutes after your tablet and says nothing about your diet otherwise. What the label restricts and what is only a suggestion draws that line properly.

Two cautions are worth attaching to it.

Fibre without fluid can make things worse. Bulk-forming fibre works by holding water. Added to a low fluid intake and slowed transit, it adds bulk to a system that is already struggling to move it. This is a well-known failure mode of the standard advice and it is more likely on this drug than off it, because intake generally is down.

Laxatives are not interchangeable. Bulk-forming, osmotic, stimulant and softening agents behave differently, some are unsuitable if obstruction is a possibility, and several interact with other medicines. Which is why the recommendation here is a pharmacist rather than a category — they can see your full list, and it is a two-minute conversation.

There is a scheduling wrinkle specific to an oral GLP-1 that catches people out. Anything you swallow is an oral medicine as far as the 30-minute window is concerned — a fibre supplement, a laxative sachet, a magnesium tablet. The label's instruction is to wait at least 30 minutes after the semaglutide tablet before food, other beverages or other oral medications, and a morning fibre drink taken with the tablet is inside that window.

The gastroparesis line

One sentence in section 5.6 is worth knowing if delayed emptying is already part of your history:

RYBELSUS and OZEMPIC tablets are not recommended in patients with severe gastroparesis.

That is a statement about who should be taking the drug rather than about managing a symptom, and it belongs to your prescriber. It is here because people with pre-existing motility problems are the group for whom this whole page is least theoretical, and because "not recommended" is stronger language than a label uses lightly.

What is worth logging

Three columns, and the third is the one that turns an anecdote into information.

Frequency. Days between — not a vague sense. It is the number a clinician asks for first.

Fluid, roughly. Not to the millilitre. Enough to spot a week where it collapsed, which is usually the week the symptom appeared.

The dose change dates. The label ties gastrointestinal reactions to escalation, and the useful sentence at an appointment is "it started four days after the increase and settled in a fortnight" rather than "I have been bunged up for a while." Logging the symptom against the dose change is the whole of the trick.

Frequently asked questions

Does Rybelsus cause constipation?

Yes, with a number attached — it appears in the label's table of adverse reactions reported in 5% or more of patients, and is more common on the drug than on placebo. Unlike nausea it does not rise across the dose steps.

How long does constipation on Rybelsus last?

The label gives no duration for it. What it does say is that the majority of gastrointestinal reactions occurred during dose escalation, which is the pattern most people describe: appearing after a step and settling as the dose stabilises. Constipation that does not settle, or that worsens, is a reason to speak to your prescriber rather than to wait longer.

What can I take for constipation on a GLP-1?

That depends on your other medicines and conditions, which is why a pharmacist is the right first stop rather than a general recommendation. Two things apply regardless: fluid matters more than usual on this drug, and anything you swallow counts as an oral medicine for the purposes of the 30-minute window after your tablet.

When is constipation an emergency?

The pattern to act on is no stool and no gas, particularly alongside vomiting, a distended or hard abdomen, or severe pain. The label lists ileus and intestinal obstruction among the reactions reported after approval, and both need urgent assessment rather than a laxative.

Is severe constipation on the label?

Yes, in the postmarketing experience section, which lists ileus, intestinal obstruction, and severe constipation including faecal impaction. Those reports come from a population of uncertain size, so the label states that a frequency cannot be reliably estimated and causation cannot be established.

Should I stop taking it if I am constipated?

That is a prescriber's decision, not a self-directed one — the drug is treating something, and stopping changes that. What is worth doing is reporting it with dates, because the response is often about the pace of the ladder rather than the drug itself.

Primary sources and further reading

Label sections are revised without notice. Every quotation above was read off the prescribing information on 8 September 2026.